Navigation Links
MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
Date:7/15/2010

ROCKVILLE, Md., July 15 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.  These grants will help MacroGenics further advance its Dual-Affinity Re-Targeting (DART), or bispecific antibody scaffold platform, as well as its portfolio of infectious disease product candidates.  The first of three recently awarded NIH grants will fund preclinical IND-enabling activities related to MacroGenics' Inflammation DART.  This DART specifically targets B lymphocytes with the potential to treat a broad range of autoimmune diseases including lupus, rheumatoid arthritis, multiple sclerosis and other disorders.

MacroGenics was awarded two additional NIH grants related to infectious disease pathogens.  These grants, both of which fall under NIH's "Partnerships for Biodefense Viral Pathogens," cover research and development activities to create an antibody-based therapy for Chikungunya Virus and a DART-based pan-Dengue Virus immunotherapeutic for prophylaxis and treatment of Dengue Virus.  Both viruses are insect-borne and transmitted to humans by virus-carrying mosquitoes.  Dr. Michael Diamond at Washington University in St. Louis developed the Chikungunya and Dengue antibodies and is the grantee for the Chikungunya Virus award; MacroGenics is the sub-recipient.

MacroGenics also announced today the publication of two articles related to its DART platform.  These articles appeared in the July 2010 issue of Arthritis & Rheumatism(1) and the June 2010 issue of Journal of Molecular Biology(2).  In addition, progress with respect to the company's DART platform has been presented at several recent scientific conferences.

This platform has broad potential applications for developing novel therapeutics.  These include approaches to signaling immune-mediated cells to treat autoimmune disorders, the redirecting of immune cells to kill tumors and inhibition of different signaling pathways required for tumor growth.  Furthermore, this technology is especially promising for treating certain infectious diseases, as it enables the targeting of two serotypes of a pathogen with a single molecule.

"We have made tremendous progress on our DART platform," said Dr. Scott Koenig, President and CEO.  "We believe we have the ability to create highly potent DART-based therapeutics and the funding from NIH will help us move forward two product candidates based on our proprietary platform."

Background on DART

MacroGenics' DART technology is focused on dual specificity antibody-based therapeutic proteins, which enables the creation of highly stable, recombinant molecules that can simultaneously target two different antigens. DART therapeutics can accommodate virtually any variable region sequence in a "plug-and-play" fashion, are potent, and have very favorable manufacturing properties.  To date, the company has engineered over 60 different DART molecules and has completed multiple in vitro and in vivo proof-of-concept studies with several prototypes.  The company has been able to produce DART molecules in both bacterial and mammalian expression systems. DARTs also have been engineered with an Fc domain, which confers them with additional properties, such as Fc receptor binding and extended half-life.  This functionality can be further expanded with the inclusion of MacroGenics' proprietary Fc domain portfolio.  MacroGenics has established and continues to expand a patent estate around the DART technology.

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases.  Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development.  The company's product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) DART, which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  These powerful sets of capabilities and technology platforms have enabled MacroGenics to build a proprietary pipeline of innovative product candidates.  The company's lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune diseases.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law. 

(1) Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. Therapeutic control of b-cell activation via recruitment of Fcgamma receptor IIB (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum, 2010 Mar 30;62(7):1933-43.

(2) Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion. J Mol Biol, 2010 Apr 9;399(3):436-49.


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MacroGenics Raises $25M in Series D-2 Financing
2. MacroGenics Appoints New Vice President of Business Development
3. Paulo F. Costa Joins MacroGenics Board of Directors
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):